Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 11Unknown 3Terminated 3Recruiting 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 64Head & Neck 28Thoracic 19Other solid neoplasm 11Tumor-Agnostic 5Gynecologic 3CNS 3Breast 3Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Colorectal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Fulvestrant 78pembrolizumab 77Carboplatin 73Capecitabine 69Trastuzumab 66Letrozole 62Cyclophosphamide 61Paclitaxel 60Specimen Handling 52pertuzumab 48Docetaxel 48abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 34Tamoxifen 33Blood Specimen Collection 33sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27pyrotinib 26eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Cetuximab × Breast × Clear all
NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Pfizer

Phase 1 Recruiting
260 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Recruiting
113 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡